Back to Search
Start Over
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
- Source :
- Advances in Therapy. 40:1153-1170
- Publication Year :
- 2023
- Publisher :
- Springer Science and Business Media LLC, 2023.
- Subjects :
- Pharmacology (medical)
General Medicine
Subjects
Details
- ISSN :
- 18658652 and 0741238X
- Volume :
- 40
- Database :
- OpenAIRE
- Journal :
- Advances in Therapy
- Accession number :
- edsair.doi...........a3ef10038bd4943075dba2d66d110cdc